新生儿低血糖症的发病率和危险因素后羟苄羟麻黄碱治疗早产:回顾性队列研究。
文章的细节
-
引用
复制到剪贴板 -
Shimokawa年代,坂田,日本须贺Y, Isoda K, Itai年代,K,岛田T、Y赛
新生儿低血糖症的发病率和危险因素后羟苄羟麻黄碱治疗早产:回顾性队列研究。
J制药医疗科学。2019年4月16日;7。doi: 10.1186 / s40780 - 019 - 0137 - 3。eCollection 2019。
- PubMed ID
-
31019720 (在PubMed]
- 文摘
-
背景:盐酸羟苄羟麻黄碱(RD) beta2-adrenergic受体激动剂,被广泛用作相关药物来抑制早产,但可引起新生儿低血糖,一个潜在的严重副作用。我们检查了新生儿低血糖的发生率和危险因素后产妇静脉RD管理。方法:这是一个回顾性研究新生儿的出生体重的> / = 2000 g和妊娠36周交货或在金泽大学医院从2013年8月到2016年7月。我们将新生儿低血糖症定义为血糖水平< 50 mg / dL。新生儿未交付产妇静脉RD或被交付后8天以上停止孕产妇RD或接受口头采访被定义为RD non-administration集团,而交付后7天内停止孕产妇RD被定义为RD静脉管理组。我们检查了RD-induced新生儿低血糖的发生率和危险因素比较这两组。结果:在这项研究中我们招收了603名新生儿;504人(83.6%)没有显示新生儿低血糖症,99例(16.4%)表现出新生儿低血糖。新生儿低血糖的发生率更高(61.7%;58/94)RD静脉管理组比RD non-administration组(8.1%;41/509)(p < 0.001)。 Binomial logistic regression analysis in the RD intravenous administration group showed that maternal age over 35 years (AOR: 3.385; 95% CI, 1.082-10.588, p = 0.036) and the interval to delivery from stopping intravenous administration of RD (AOR: 0.974; 95% CI, 0.953-0.996, p = 0.020) were independent factors associated with neonatal hypoglycemia. The cut-off value of the interval to predict the incidence of neonatal hypoglycemia was about 6 h (sensitivity 82.8%, specificity 63.9%). CONCLUSIONS: The incidence of neonatal hypoglycemia was significantly increased by maternal intravenous administration of RD. We newly identified maternal age (over 35 years) and the interval to delivery from stopping intravenous administration of RD (within 6 h) as independent risk factors for neonatal hypoglycemia following maternal intravenous administration of RD. In cases with these risk factors, careful blood glucose monitoring is recommended for early detection and treatment of neonatal hypoglycemia.